FOLLOW-UP CASES OF BEDAQUILINE IN XDR-TB PATIENTS: A CASE SERIES
DOI:
https://doi.org/10.22159/ajpcr.2024.v17i3.49158Keywords:
Bedaquiline, XDR-TB, NTEPAbstract
Tuberculosis has consistently maintained its lead position in being among the top 10 causes by means of single-cause etiology for death among infectious disease patients. On top of it, now multi-drug resistant cases of tuberculosis (MDR-TB) are raising concern. The vision of tuberculosis eradication gets a major setback with a total of 206,030 million cases being reported worldwide with MDR or rifampicin-resistance MDR-TB in 2019. Bedaquilline a relative recent drug is being made available for the treatment of MDR and extensive drug resistance (XDR) TB under NTEP. It is being provided as a part of 2nd line of drug therapy. Regarding the drug’s efficacy and safety profiling Bedaquiline has been under extensive clinical trials at medical institutes and hospitals of reputation at national level. The treatment options available to treat XDR-TB remain extremely limited at the cost of being less effective, expensive and with more side effects. Even after the availability of potent anti-tubercular drugs, XDR Tuberculosis is proving to be more resistant to all possible drugs available to work against it.
Downloads
References
World Health Organization. Global Tuberculosis Report 2017. Geneva: World Health Organization; 2017. Available from: https://www.who. int/publications/i/item/9789241565516
TB. Available from: https://www.who.int/publications/i/ item/9789240037021 [Last accessed on 2021 Feb 20].
Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005;307:223-7. doi: 10.1126/ science.1106753
Sarathy JP, Gruber G, Dick T. Re-understanding the mechanisms of action of the anti-mycobacterial drug bedaquiline. Antibiotics (Basel) 2019;8:261. doi: 10.3390/antibiotics8040261
Van Anh Nguyen T, Anthony RM, Bañuls AL, Van Anh Nguyen T, Vu DH, Alffenaar JC. Bedaquiline resistance: Its emergence, mechanism, and prevention. Clin Infect Dis 2018;66:1625-30. doi: 10.1093/cid/cix992
Somoskovi A, Bruderer V, Hömke R, Bloemberg GV, Böttger EC. A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J 2015;45:554-7. doi: 10.1183/09031936.00142914, PMID 25359333
Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:2979-81. doi: 10.1128/aac.00037-14, PMID: 24590481; PMCID: PMC3993252
Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, et al. Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: Lessons to avoid repeating past errors. Eur Respir J 2017;49:1601719. doi: 10.1183/13993003.01719-2016, PMID 28182568
Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: Great promise or disappointment? Ther Adv Chronic Dis 2015;6:170-84. doi: 10.1177/2040622315582325, PMID 26137207; PMCID: PMC4480545
Xu J, Wang B, Hu M, Huo F, Guo S, Jing W, et al. Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2017;61:e00239-17. doi: 10.1128/AAC.00239-17, PMID 28320727; PMCID: PMC5444180
Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, et al. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother 2017;72:684-90. doi: 10.1093/ jac/dkw502, PMID 28031270; PMCID: PMC5400087
Centers for Disease Control and Prevention. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multi Drug Resistant Tuberculosis. Atlanta, GA: CDC; 2013. Available from: https://www.cdc.gov/mmwr/ preview/mmwrhtml/rr6209a1.htm
Pandie M, Wiesner L, McIlleron H, Hughes J, Siwendu S, Conradie F. Drug-drug interactions between bedaquiline and the antiretrovirals lopinavir/ritonavir and nevirapine in HIV-infected patients with drug-resistant TB. J Antimicrob Chemother 2016;71:1037-40.
Svensson EM, Murray S, Karlsson MO, Dooley KE. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother 2015;70:1106-14. doi: 10.1093/ jac/dku504, PMID 25535219; PMCID: PMC4356204
Drucker D, Eggo MC, Salit IE, Burrow GN. Ethionamide-induced goitrous hypothyroidism. Ann Intern Med 1984;100:837-9. doi: 10.7326/0003-4819-100-6-837
World Health Organization. Guidelines for the Programmatic management of drug-resistant tuberculosis: Emergency Update 2008. WHO/HTM/TB/2008.402. Geneva, Switzerland: World Health Organization; 2008. Available from https://www.who.int/publications/i/item/9789241501583
Tola HH, Garmaroudi G, Shojaeizadeh D, Tol A, Yekaninejad MS, Ejeta LT, et al. The Effect of psychosocial factors and patients’ perception of tuberculosis treatment non-adherence in Addis Ababa, Ethiopia. Ethiop J Health Sci 2017;27:447-58. doi: 10.4314/ejhs. v27i5.2, PMID 29217949; PMCID: PMC5615005
WHO. Guideline: Nutritional Care and Support for Patients with Tuberculosis. Geneva: World Health Organization; 2013. Available from: https://www.who.int/publications/i/item/9789241506410
WHO. The Use of Delamanid in the Treatment of Multidrug-Resistant Tuberculosis-Policy Guidance. Geneva: World Health Organization; 2014. Available from: https://www.who.int/publications/i/item/9789241549899
Published
How to Cite
Issue
Section
Copyright (c) 2023 Shahenaz Malek, Dr.Anita Sinha, Dr.Anil Singh
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
